Hang in there RD, or don’t at your own discretion. It’s your investment and you know your own situation better than anyone else.
In the spirit of clarifying the investment environment basics:
1. The phase 3 trial has been completed and the Top Line results have been revealed at the NYAS event on May 10th and again at ASCO, endpoints of mOS for nGBM and rGBM being met with statistical significance, and long tail survival benefits (including the existence of previously not seen much extended survival and effectively cured patients) established
2. Decisions have been made along the way in the face of forces opposed to dcvax success and nwbo survival, along with new learnings during the trial and changing RA and medical communities views, and challenges to continue the necessary funding over the years
3. While it is true that nwbo has been either wrong on timeline milestones and had milestones impacted by external factors, it is not unusual for prerevenue biotech companies and their efforts and timelines to be wrong and/or impacted and mostly taking longer to come to fruition
4. It’s normal for you and many nwbo longs to experience periods of varying degrees of frustration, disappointment, anticipation, etc.
5. Many “missed” timeline events are of our own creation and adaptive guesswork over the years, especially when the company has clamped down on communications and other forms of information sharing
6. Considering all the above, nwbo and the dcvax-L treatment have achieved accomplishments and the top level results are such that the chances of approvals are the highest and the existence of patients alive between 5-15 years after diagnosis of GBM speaks as strongly as possible, approval or not
